Crude and aRR of non-serious infection, by current DMARD use
| Cases (n=13 634) | Controls (n=68 170) | aRR, model 1 (95% CI) | aRR, model 2 (95% CI) | |
|---|---|---|---|---|
| Current DMARD use | ||||
| Methotrexate | 33.3 | 33.0 | 0.98 (0.94 to 1.03) | 1.00 (0.95 to 1.04) |
| Sulfasalazine | 2.4 | 3.0 | 0.81 (0.72 to 0.91) | 0.79 (0.70 to 0.89) |
| Leflunomide | 0.3 | 0.3 | 1.07 (0.76 to 1.49) | 1.00 (0.71 to 1.39) |
| CQ/HCQ | 29.4 | 30.7 | 0.91 (0.87 to 0.96) | 0.93 (0.89 to 0.98) |
| Azathioprine | 1.9 | 1.5 | 1.13 (0.99 to 1.31) | 1.05 (0.91 to 1.22) |
| Cyclophosphamide | 1.7 | 0.7 | 2.86 (2.05 to 3.99) | 2.14 (1.51 to 3.03) |
| Gold | 7.1 | 6.5 | 1.13 (1.04 to 1.23) | 1.08 (0.99 to 1.18) |
| Anti-tumour necrosis factor therapy | 0.1 | 0.1 | 1.41 (0.83 to 2.39) | 1.48 (0.87 to 2.52) |
| Others | 1.8 | 1.7 | 1.08 (0.93 to 1.25) | 1.07 (0.92 to 1.25) |
Numbers are percentages unless otherwise stated.
aRR, adjusted RR, comparing current drug use with no current drug use; CQ/HCQ, chloroquine/hydroxychloroquine; DMARD, disease-modifying antirheumatic drug; model 1, adjusted for all other drugs in the table and glucocorticoids; model 2, model 1 plus further adjusted for all other a priori confounders listed in table 2.